Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-20, Stock:NVS, The news for the past five days is as follows:
2018-04-13: NEWS1: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS2: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III.NEWS3: Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV&apos;s Drugs Succeed in Phase III.NEWS4: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS5: Bristol-Myers Collaborates With Harvard Fibrosis Network.NEWS6: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS7: Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why.NEWS8: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS9: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS10: Rigel Pharmaceuticals&apos; (RIGL) Stock Gains 16%: Here&apos;s Why.NEWS11: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS12: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS13: Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus.NEWS14: Pharma M&A Active This Week: 4 Potential Buyout Targets.NEWS15: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS16: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.NEWS17: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS18: The Swiss Stock Market Finished Nearly Unchanged In Choppy Trade.NEWS19: These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years.NEWS20: Same as the old boss — Novan makes interim CEO permanent.NEWS21: Glaxo to Sell Rare Disease Gene Therapies to Private Biotech.
2018-04-16: NEWS1: How Did Biogen Miss AveXis?.NEWS2: How Did Biogen Miss AveXis?.NEWS3: Did Novartis Overpay for AveXis?.NEWS4: Did Novartis Overpay for AveXis?.NEWS5: What Novartis Bought in AveXis.NEWS6: What Novartis Bought in AveXis.NEWS7: Did Novartis Overpay for AveXis?.NEWS8: How Did Biogen Miss AveXis?.NEWS9: What Novartis Bought in AveXis.NEWS10: Gilead (GILD) Presents Encouraging Data on NASH Therapies.NEWS11: Gilead (GILD) Presents Encouraging Data on NASH Therapies.NEWS12: VXUS, NSRGY, NVS, BTI: ETF Inflow Alert.NEWS13: VXUS, NSRGY, NVS, BTI: ETF Inflow Alert.NEWS14: The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte.NEWS15: The Swiss Stock Market Dropped As NestlÃ© Goes Ex-Dividend.NEWS16: The Swiss Stock Market Dropped As NestlÃ© Goes Ex-Dividend.NEWS17: NVS: Entresto Preserves Kidney Function In Diabetic Patients With Chronic HF.NEWS18: NVS: Entresto Preserves Kidney Function In Diabetic Patients With Chronic HF.
2018-04-17: NEWS1: 5 Biotech IPOs to Watch in April.NEWS2: 5 Biotech IPOs to Watch in April.NEWS3: Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria.NEWS4: Novartis’s Innovative Medicines Segment in 1Q18.NEWS5: What's in Store for Novartis (NVS) This Earnings Season?.NEWS6: What's in Store for Novartis (NVS) This Earnings Season?.NEWS7: Novartis’s 1Q18: Analysts Expect Revenue Growth.NEWS8: What&apos;s in Store for Novartis (NVS) This Earnings Season?.NEWS9: Expectations from Novartis’s 1Q18 Earnings.NEWS10: Risankizumab Could Be AbbVie’s Long-Term Growth Driver.NEWS11: The Swiss Stock Market Rebounded As Syria Concerns Relax.NEWS12: The Swiss Stock Market Rebounded As Syria Concerns Relax.NEWS13: Novartis tender offer for AveXis commences.NEWS14: Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts.NEWS15: Novartis Unit Commences Tender Offer For AveXis Stock - Quick Facts.
2018-04-18: NEWS1: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.NEWS2: Sandoz Signs Deal With Pear Therapeutics.NEWS3: Sandoz Signs Deal With Pear Therapeutics.NEWS4: Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio.NEWS5: How Exelixis’s Cabomeytx and Cometriq Performed in 4Q17 and 2017.NEWS6: Pre-Market Earnings Report for April 19, 2018 :  PM, DHR, BK, TSM, BBT, PPG, NVS, BX, NUE, KEY, GWW, DGX.NEWS7: Pre-Market Earnings Report for April 19, 2018 :  PM, DHR, BK, TSM, BBT, PPG, NVS, BX, NUE, KEY, GWW, DGX.NEWS8: Amgen's Aimovig Reduces Episodic Migraine in 30% Patients.NEWS9: Amgen's Aimovig Reduces Episodic Migraine in 30% Patients.NEWS10: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS11: Major Averages Close Mixed Following Lackluster Session - U.S. Commentary.NEWS12: Analysts’ Recommendations for Novartis on April 17.NEWS13: Amgen&apos;s Aimovig Reduces Episodic Migraine in 30% Patients.NEWS14: Novartis’s 1Q18 Estimates: Expectations for Alcon.NEWS15: The Swiss Stock Market Inched Higher As Investors Pause.NEWS16: The Swiss Stock Market Inched Higher As Investors Pause.NEWS17: Novartis’s 1Q18 Estimates: Expectations for Sandoz.
2018-04-19: NEWS1: Novartis AG (ADR) Stock Drops on Q1 Earnings Miss.NEWS2: Novartis AG (ADR) Stock Drops on Q1 Earnings Miss.NEWS3: Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript.NEWS4: Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript.NEWS5: Novartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint.NEWS6: Health Care Sector Update for 04/19/2018: AGN,SHPG,GILD,NVS,DHR.NEWS7: Health Care Sector Update for 04/19/2018: AGN,SHPG,GILD,NVS,DHR.NEWS8: Novartis AG (ADR) Stock Drops on Q1 Earnings Miss.NEWS9: Health Care Sector Update for 04/19/2018: GILD,NVS,DHR.NEWS10: Health Care Sector Update for 04/19/2018: GILD,NVS,DHR.NEWS11: Novartis AG (NVS) Q1 2018 Earnings Conference Call Transcript.NEWS12: Novartis (NVS) Beats Earnings and Revenue Estimates in Q1.NEWS13: Health Care Sector Update for 04/19/2018: NVS, DHR, ALGN, GILD, 4503.T.NEWS14: Health Care Sector Update for 04/19/2018: NVS, DHR, ALGN, GILD, 4503.T.NEWS15: SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS.NEWS16: Sanofi to Divest European Generic Unit, Streamline Business.NEWS17: The Swiss Stock Market Finished Nearly Flat After Paring Early Gains.NEWS18: The Swiss Stock Market Finished Nearly Flat After Paring Early Gains.NEWS19: Novartis CEO feels heat on U.S. generics, Cosentyx drop.NEWS20: European Markets Finished Little Changed In Directionless Trade.NEWS21: European Markets Finished Little Changed In Directionless Trade.NEWS22: Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver.NEWS23: Novartis Earnings Top, But Key Drug, Generics Sales Disappoint.NEWS24: Earnings Reaction History: Novartis AG, 55.6% Follow-Through Indicator, 2.2% Sensitive.NEWS25: Earnings Reaction History: Novartis AG, 55.6% Follow-Through Indicator, 2.2% Sensitive.NEWS26: Novartis: 1Q Earnings Snapshot.NEWS27: [$$] Cancer and heart drugs boost Novartis sales .NEWS28: Novartis 1Q profit jumps 12 percent as heart drug sales soar.NEWS29: Novartis 1Q profit jumps 12 percent as heart drug sales soar.NEWS30: [$$] Novartis Buoyed by Heart Drug.NEWS31: [$$] Greek parliament ends probe into bribery allegations.NEWS32: European Shares Hold Steady Amid Earnings Deluge.NEWS33: European Shares Hold Steady Amid Earnings Deluge.NEWS34: Novartis Q1 Profit Climbs, Misses Estimates; Backs FY18 View - Quick Facts.NEWS35: Novartis Q1 Profit Climbs, Misses Estimates; Backs FY18 View - Quick Facts.NEWS36: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.NEWS37: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.

Answer: Decrease